Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13DFiled 9 h ago

SpyGlass Pharma, Inc.: Vensana Capital I GP, LLC amends Schedule 13D stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13D, sec.gov, 18 November 2026, by SEC EDGAR SCHEDULE 13D

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Vensana Capital I GP, LLC filed an amended Schedule 13D with the SEC (accession 0001193125-26-467227) covering its stake in SpyGlass Pharma, Inc. The amendment updates the fund's previously reported beneficial ownership position in the ophthalmic drug-delivery company. Schedule 13D filings signal activist or influential holder status, so changes in the reported stake can indicate shifts in investor conviction. Specific share counts and percentage figures were not detailed in the filing headline. Investors will watch for further 13D amendments or Form 4 insider filings to gauge Vensana's intentions.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.

Named in this story

Vensana Capital I GP, LLC, SpyGlass Pharma, Inc.